Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Smith

Showing results (291-300 of 303) with videos related to

Pageof 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2016
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid LeukemiaIvana Gojo, Jan H Beumer, Keith W Pratz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJerald P Radich, Michael Deininger, Camille N Abboud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older AdultsYvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.
Haematologica|November 16, 2016
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R McCurdy, Yvette L Kasamon, Christopher G Kanakry, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Arnel Pallera, Jessica K Altman, Ellin Berman, et al.
Blood Advances|October 20, 2020
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamideJonathan A Webster, Leo Luznik, Hua-Ling Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2023
CML and the WHO: Why?Ellin Berman, Neil P Shah, Michael Deninger, et al.
Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P Shah, Ravi Bhatia, Jessica K Altman, et al.
Blood|January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseMark Levis, Farhad Ravandi, Eunice S Wang, et al.
Pageof 31

Showing results (291-300 of 303) with videos related to

Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2016
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid LeukemiaIvana Gojo, Jan H Beumer, Keith W Pratz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2018
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJerald P Radich, Michael Deininger, Camille N Abboud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older AdultsYvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.
Haematologica|November 16, 2016
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R McCurdy, Yvette L Kasamon, Christopher G Kanakry, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Arnel Pallera, Jessica K Altman, Ellin Berman, et al.
Blood Advances|October 20, 2020
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamideJonathan A Webster, Leo Luznik, Hua-Ling Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2023
CML and the WHO: Why?Ellin Berman, Neil P Shah, Michael Deninger, et al.
Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P Shah, Ravi Bhatia, Jessica K Altman, et al.
Blood|January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseMark Levis, Farhad Ravandi, Eunice S Wang, et al.
Pageof 31